Stark vorbehandelte Hodgkin-Patienten profitieren von Pembrolizumab

52. Jahrestagung der American Society of Clinical Oncology (ASCO), 3.–7. Juni 2016, Chicago. Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia, 6. Juni 2016

[1] Horning S et al., Ann Oncol 2008; 19 (Suppl 4): 120, Abstract 118

[2] https://ash.confex.com/ash/2015/webprogram/Paper85725.html. Letzter Aufruf: 10. Juni 2016

[3] Chen RW et al., J Clin Oncol, 2016; 34 (Suppl): Abstract 7555